摘要
将90例伴有胃肠道症状、幽门螺杆菌(Hp)阳性的患者分为莫西沙星组和对照组,给予Hp根除治疗。结果显示,莫西沙星组较对照组胃肠道症状改善明显、不良反应发生率少、Hp根除率高,均P<0.05;治疗前、后两组的总有效率比较差异无统计学意义(P>0.05)。提示以莫西沙星为基础的三联疗法对根除患者Hp感染有很好的疗效,并不良反应低。
Ninety patients with positive helicobacter pylori（Hp） and gastrointestinal symptoms who underwent Hp eradication therapy were randomly divided into two groups,patients in trial group received moxifloxacin 400mg q.d,esomeprazole 20mg b.i.d and metronidazole 400mg b.i.d;patients in control group received esomeprazole 20mg b.i.d,clarithromyein 0.5 b.i.d and amoxieillin 1.0 b.i.d.The change of gastrointestinal symptoms before and after therapy,the side effect of medications,rate of Hp eradication were compared between two groups.Comparing the control group,the gastrointestinal symptoms in trial group were improved significantly with less side effects and higher rate of Hp eradication（all P0.05）.Before therapy there were no differences in the total effective rate between two groups.Tne results indicate that patients with Hp infection should receive moxifloxacin-based triple therapy as first-line treatment.
出处
《医学信息（中旬刊）》
2011年第3期806-807,共2页
Medical Information Operations Sciences Fascicule
关键词
莫西沙星
螺杆菌
幽门
Moxifloxacin
Helicobacter
Pylori
